GoodRx Holdings
GDRX
Market cap $1.64B

4.29 USD

-0.02

0.46%

At close Nov 21, 4:00 PM EST

After hours

4.29

+0.00

0.00%

1 day

-0.46%

5 days

-4.67%

1 month

-35.10%

3 months

-42.72%

6 months

-40.08%

Year to date

-23.67%

1 year

-23.26%

5 years

-91.50%

10 years

-91.50%

About: GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

Employees: 694

Information Technology Computer Processing & Data Preparation

0

Funds holding %

of 6,747 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

53% more call options, than puts

Call options by funds: $6.04M | Put options by funds: $3.95M

3.35% more ownership

Funds ownership: 140.71% [Q2] → 144.07% (+3.35%) [Q3]

3% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 36

1% more funds holding

Funds holding: 163 [Q2] → 164 (+1) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

5% less capital invested

Capital invested by funds: $1.04B [Q2] → $986M (-$49.7M) [Q3]

21% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 47

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

40%

upside

Avg. target

$6.50

52%

upside

High target

$7

63%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Citigroup Daniel Grosslight 100% 1-year accuracy 2 / 2 met price target	63%upside $7	Buy Maintained	13 Nov 2024
Barclays Stephanie Davis 50% 1-year accuracy 2 / 4 met price target	40%upside $6	Overweight Maintained	11 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 17 articles about GDRX published over the past 30 days

GoodRx Helps Announces Recipients of 2024 Students for Healthcare Equity Scholarship

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Helps, a 501(c)(3) nonprofit organization seeking to address health inequities across the country, has selected its 2024 Students for Healthcare Equity Scholarship recipients. The scholarship program was created to encourage culturally responsive healthcare by providing financial assistance to healthcare students from underrepresented groups. To date, GoodRx Helps has granted $325,000 in scholarships to students advocating for equitable access to he.

GoodRx Helps Announces Recipients of 2024 Students for Healthcare Equity Scholarship

Kuehn Law Encourages Investors of GoodRx Holdings, Inc. to Contact Law Firm

NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of GoodRx Holdings, Inc. (NASDAQ: GDRX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, GoodRx insiders caused the company to misrepresent or fail to disclose that (1) while Kroger accounted for less than 5% of the pharmacies accepting GoodRx discounts, Kroger was responsible for nearly 25% of GoodRx's total prescription transactions revenue (the Company's primary revenue stream); and (2) Kroger could unilaterally cease accepting GoodRx discounts, cutting off some or all of GoodRx's revenues for purchases at Kroger's pharmacies; and (3) as a result, representations about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Kuehn Law Encourages Investors of GoodRx Holdings, Inc. to Contact Law Firm

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ophthalmic pharmaceutical products. This effort includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., providing patients with discounts on select Harrow products. This.

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

GOODRX ALERT: Bragar Eagel & Squire, P.C. is Investigating GoodRx Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (NASDAQ: GDRX) on behalf of long-term stockholders following a class action complaint that was filed against GoodRx on April 22, 2024 with a Class Period from September 23, 2020, to November 8, 2022. Our investigation concerns whether the board of directors of GoodRx have breached their fiduciary duties to the company.

GOODRX ALERT: Bragar Eagel & Squire, P.C. is Investigating GoodRx Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

The Motley Fool

Why GoodRx Holdings Stock Was Sinking This Week

The company is growing key fundamentals. However, the improvements weren't enough to impress the market.

Why GoodRx Holdings Stock Was Sinking This Week

GoodRx Holdings, Inc. (GDRX) Q3 2024 Earnings Call Transcript

GoodRx Holdings, Inc. (GDRX) Q3 2024 Earnings Call Transcript

GoodRx Holdings, Inc. (GDRX) Q3 2024 Earnings Call Transcript

Zacks Investment Research

GoodRx (GDRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

GoodRx (GDRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

GoodRx Holdings, Inc. (GDRX) Misses Q3 Earnings and Revenue Estimates

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.06 per share a year ago.

GoodRx Holdings, Inc. (GDRX) Misses Q3 Earnings and Revenue Estimates

GoodRx Reports Third Quarter 2024 Results

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $195.3 million Net income of $4.0 million; Net income margin of 2.0% Adjusted Net Income1 of $31.9 million; Adjusted Net Income Margin1 of 16.4% Adjusted EBITDA1 of $65.0 million; Adjusted.

GoodRx Reports Third Quarter 2024 Results

Zacks Investment Research

GoodRx (GDRX) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

Beyond analysts' top -and-bottom-line estimates for GoodRx (GDRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.

GoodRx (GDRX) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

See News Rankings

Charts implemented using Lightweight Charts™